The human liver plays a pivotal role in drug metabolism, largely attributable to the diverse family of UDP-glucuronosyltransferases (UGTs) that catalyse glucuronidation reactions. This conjugation ...

International study looked at 800 patients in 37 countries Patients getting the drug saw less inflammation and fat in their livers Lead researcher says it could help treat liver disease like MASH ...

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in ...

Metabolic dysfunction–associated steatotic liver disease (MASLD) has become the most common liver disease worldwide, with a global prevalence of 32.4%. Its growth over the past three decades has ...

Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the ...

At the recent American Association of Clinical Endocrinology (AACE) annual meeting, leaders highlighted major advances in endocrine care, particularly around obesity and metabolic liver disease. In ...

Scientists at UC San Diego have identified a new drug, ION224, that could transform the treatment of MASH, a dangerous form of fatty liver disease tied to obesity and diabetes. By blocking a key liver ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...